GlassScriptPhysician profile
Frank Duperier
NPI 1609864909
$8,213.77
in general payments reported to CMS, 2019-2025
28 companies · $4,552 in 2025
The $4,552 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $175 · 2021: $184 · 2022: $738 · 2023: $644 · 2024: $736 · 2025: $4,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Travel and Lodging: $2,280 · Consulting Fee: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.29 |
| Travel and Lodging | $2,280.14 |
| Consulting Fee | $560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,887.21 | 2019-2025 | |
| Medtronic, INC. | $2,567.47 | 2023-2025 | Signia, Ligasure |
| Stryker Corporation | $928.80 | 2019-2021 | |
| Lexington Medical, INC. | $646.66 | 2021-2025 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Novo Nordisk INC | $268.08 | 2020-2024 | Wegovy, Saxenda |
| Baxter Healthcare | $137.59 | 2019-2025 | Tisseel |
| Corcept Therapeutics | $112.68 | 2024 | Korlym |
| Ethicon US, LLC | $93.20 | 2019-2025 | Vistaseal, Echelon Flex, Echelon Endopath |
| Vertex Pharmaceuticals Incorporated | $64.22 | 2025 | |
| Lilly USA, LLC | $58.18 | 2024-2025 | Zepbound |
| Intra-Sana Laboratories | $50.76 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Endo Pharmaceuticals INC. | $42.60 | 2019-2020 | |
| Daiichi Sankyo INC. | $40.50 | 2019-2020 | |
| Davol INC. | $40.29 | 2024-2025 | Phasix Mesh, Surgiphor |
| Covidien LP | $34.48 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $29.57 | 2019 | |
| Fisher & Paykel Healthcare INC | $25.62 | 2023 | Fisher & Paykel Healthcare |
| Standard Bariatrics, INC. | $24.05 | 2022 | |
| Eisai INC. | $22.45 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $20.94 | 2025 | Exparel |
| Medinc of Texas | $18.32 | 2022 | |
| Innocoll Pharmaceuticals Limited | $16.45 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $15.72 | 2024 | Imcivree |
| Eagle Pharmaceuticals, INC. | $15.19 | 2022 | |
| Lsi Solutions INC | $14.61 | 2023 | Running Device |
| Vivus LLC | $13.65 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.36 | 2019 | |
| Currax Pharmaceuticals LLC | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Duperier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.